These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2441734)

  • 1. Depressed fibrinolysis in patients with acute leukaemia.
    Guarini A; Mussoni L; Gugliotta L; Chetti L; Niewiarowski T; Catani L; Macchi S; Donati MB; Tura S
    Br J Haematol; 1987 Jul; 66(3):327-30. PubMed ID: 2441734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
    Auwerx J; Bouillon R; Collen D; Geboers J
    Arteriosclerosis; 1988; 8(1):68-72. PubMed ID: 2449156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
    Omran SA; Madkour BA; Essawy FM; Toima SM; el Kaliouby AH; Shams el Din AA
    Blood Coagul Fibrinolysis; 1992 Dec; 3(6):819-22. PubMed ID: 1489902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
    Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
    Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
    Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
    Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit.
    Voss R; Matthias FR; Borkowski G; Reitz D
    Br J Haematol; 1990 May; 75(1):99-105. PubMed ID: 1695855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.
    Glas-Greenwalt P; Hall JM; Panke TW; Kant KS; Allen CM; Pollak VE
    J Lab Clin Med; 1986 Nov; 108(5):415-22. PubMed ID: 2430036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of coagulation-fibrinolysis system and platelet function in patients with vertigo.
    Noda Y; Nakamura M; Sasaki M; Kosugi T
    Auris Nasus Larynx; 1986; 13 Suppl 1():S75-9. PubMed ID: 2429647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis after hip replacement. Relationship to the fibrinolytic system.
    Eriksson BI; Eriksson E; Gyzander E; Teger-Nilsson AC; Risberg B
    Acta Orthop Scand; 1989 Apr; 60(2):159-63. PubMed ID: 2471386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery.
    Páramo JA; Rifón J; Llorens R; Casares J; Paloma MJ; Rocha E
    Haemostasis; 1991; 21(1):58-64. PubMed ID: 1907591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diurnal variation of the fibrinolytic system.
    Grimaudo V; Hauert J; Bachmann F; Kruithof EK
    Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the blood fibrinolytic enzyme system of patients with cutaneous vasculitis.
    Toki N; Yamura T
    Br J Dermatol; 1980 Jul; 103(1):41-50. PubMed ID: 6775670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of the enzyme preparation longolytin on fibrinolysis in animals].
    Serebriakova TN; Andreenko GV; Tsymanovich SG; Maksimova RA; Sharkova TS
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1985; (2):66-71. PubMed ID: 3157406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic and protease inhibitory systems in spinal cord injured patients with end-stage renal disease.
    Vaziri ND; Winer RL; Gonzales EV; Eltorai IM
    J Am Paraplegia Soc; 1993 Jul; 16(3):149-52. PubMed ID: 7690062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severity of coronary artery disease and basal fibrinolysis.
    Small M; Lowe GD; Beattie JM; Hutton I; Lorimer AR; Forbes CD
    Haemostasis; 1987; 17(5):305-11. PubMed ID: 2444504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
    Mellbring G; Dahlgren S; Wiman B
    Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The study of local fibrinolysis in abortion.
    Ikeuchi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jul; 37(7):1215-23. PubMed ID: 2411832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis and antithrombin in acute leukaemia.
    Laursen B
    Dan Med Bull; 1976 May; 23(2):81-6. PubMed ID: 59658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.